Evidence map›Paper›PMID 21551244›Full record

ArticleCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2011

Oral contraceptive use and survival in women with invasive breast cancer.

Yani Lu, Huiyan Ma, Kathleen E Malone, Sandra A Norman, Jane Sullivan-Halley, Brian L Strom, Michael S Simon, Polly A Marchbanks, Jill A McDonald, Dee W West and 4 more

Abstract read
In one paragraph

Article in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Breast Cancer Risk Factors and Survival by Tumor Subtype: Pooled Analyses from the Breast Cancer Association Consortium.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2021
    Article
  3. Article
  4. Article
  5. Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yani LuDivision of Cancer Etiology, Department of Population Sciences, City of Hope National Medical Center, Duarte, CA 91010, USA. yalu@coh.org
Huiyan Ma
Kathleen E Malone
Sandra A Norman
Jane Sullivan-Halley
Brian L Strom
Michael S Simon
Polly A Marchbanks
Jill A McDonald
Dee W West
Katherine D Henderson
Dennis Deapen
Giske Ursin
Leslie Bernstein

Funding

CALIFORNIA TEACHERS STUDYR01CA077398 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI BERNSTEIN, LESLIE · 1998 to 2014
$29.7M
SURVEILLANCE EPIDEMIOLOGY &END RESULTS PROGRAMN01PC067010 · PC · UNIVERSITY OF SOUTHERN CALIFORNIA · PI ROSS, RONALD K · 1996 to 2000
$2.4M
SURVEILLANCE EPIDEMIOLOGY &END RESULTS PROGRAMN01PC067006 · PC · EMORY UNIVERSITY · PI YOUNG, JOHN L · 1996 to 2000
$1.7M
BREAST CANCER AND THE BIRTH CONTROL PILL-275923166N01HD023166 · NICHD · FRED HUTCHINSON CANCER RESEARCH CENTER · 1992 to 2003
$1.4M
Research and Mentoring on Energetic Factors and Cancer: Established InvestigatorK05CA136967 · NCI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI BERNSTEIN, LESLIE · 2009 to 2013
$684k
BREAST CANCER AND THE BIRTH CONTROL PILL-275933175N01HD033175 · NICHD · UNIVERSITY OF SOUTHERN CALIFORNIA · 1993 to 2003
$298k
BREAST CANCER AND THE BIRTH CONTROL PILL-275933176N01HD033176 · NICHD · UNIVERSITY OF PENNSYLVANIA INC · 1993 to 2003
$110k
BREAST CANCER AND THE BIRTH CONTROL PILL-275933168N01HD033168 · NICHD · EMORY UNIVERSITY (INC) · 1993 to 2003
$8k
BREAST CANCER AND THE BIRTH CONTROL PILLN01HD033174 · NICHD · BARBARA ANN KARMANOS CANCER INSTITUTE · PI SMITH, LINDA K · 1993 to 2000
$0k
NEONATAL NITROGEN METABOLISM: STABLE ISOTOPE STUDIESR01HD023168 · NICHD · CHILDREN'S HOSPITAL OF PHILADELPHIA · PI YUDKOFF, MARC · 1987 to 1989
–
SURVEILLANCE EPIDEMIOLOGY AND END RESULTSN01CN005230 · CN · FRED HUTCHINSON CANCER RESEARCH CENTER · PI THOMAS, DAVID B · 1990 to 1996
–
SURVEILLANCE, EPIDEMIOLOGY, AND END RESULTS--SEERN01CN065064 · CN · WAYNE STATE UNIVERSITY · PI WEISS, LINDA K · 1996 to 1997
–
NCI NIH HHS K05 CA136967NCI NIH HHS N01 CN005230NCI NIH HHS N01 CN065064NCI NIH HHS N01-CN-65064NCI NIH HHS N01 PC035136NCI NIH HHS N01 PC035139NCI NIH HHS N01 PC067006NCI NIH HHS N01 PC067010NCI NIH HHS N01-PC-35136NCI NIH HHS N01-PC-35139NCI NIH HHS N01-PC-67006NCI NIH HHS N02 PC015105NCI NIH HHS R01 CA077398NCI NIH HHS R01 CA77398NICHD NIH HHS N01 HD023166NICHD NIH HHS N01 HD033168NICHD NIH HHS N01 HD033174NICHD NIH HHS N01 HD033175NICHD NIH HHS N01 HD033176NICHD NIH HHS N01-HD-2-3166NICHD NIH HHS N01-HD-2-3168NICHD NIH HHS N01-HD-3-3174NICHD NIH HHS N01-HD-3-3175NICHD NIH HHS N01-HD-3-3176NICHD NIH HHS Y01 HD007022NICHD NIH HHS Y01-HD-7022
6 · The paper itself

Abstract

backgroundOral contraceptives (OC) are widely used in the United States. Although the relation between OC use and breast cancer incidence has been widely studied, the few studies examining associations between OC use prior to breast cancer diagnosis and survival are inconsistent.

methodsWomen with invasive breast cancer participating in the Women's Contraceptive and Reproductive Experiences (CARE) Study, a population-based case-control study (4565 women ages 35-64 years), and the California Teachers Study (CTS) cohort (3929 women ages 28-91 years) were followed for vital status. A total of 1,064 women died in the CARE Study (median follow-up, 8.6 years) and 523 died in the CTS (median follow-up, 6.1 years). Cox proportional hazards regression provided hazard rate ratio estimates [(relative risk, RR)] with 95% confidence intervals (CIs) for risk of death from any cause and from breast cancer.

resultsNo association was observed for any OC use prior to diagnosis and all-cause mortality [CARE Study: RR = 1.01 (95% CI = 0.86-1.19); CTS: RR = 0.84 (95% CI = 0.67-1.05)]. A decreased risk of all-cause mortality was observed in the CTS among women with more than 10 years of OC use (RR = 0.67, 95% CI = 0.47-0.96); however, no trend of decreasing risk with increasing OC duration was observed (P(trend) = 0.22), and no association was observed in the CARE study. No associations were observed for breast cancer-specific mortality.

conclusionsOC use is not associated with all-cause or breast cancer-specific mortality among women with invasive breast cancer. IMPACT: These 2 independent studies demonstrated no overall association between OC use and survival among women with breast cancer.

Indexed as

AdultAgedAged, 80 and overBreast NeoplasmsCase-Control StudiesCohort StudiesContraceptives, OralFemaleHumansMiddle AgedNeoplasm InvasivenessProportional Hazards ModelsYoung AdultContraceptives, Oral

Identifiers

PMID21551244
PMCPMC3132273

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.